One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection

doi:10.19803/j.1672-8629.20250180

Abstract

Abstract: Objective To explore such adverse reactions as autoimmune hemolytic anemia (AIHA) caused by camrelizumab for injection in order to provide a reference for safe medications. Methods One case of severe anemia following the use of an immune checkpoint inhibitor (ICI) in a patient with parotid gland carcinoma was analyzed based on related literature. Results Based on the patient’s medical history, results of laboratory tests, and the timing of drug administration, the patient’s AIHA was considered an adverse reaction caused by camrelizumab for injection. Conclusion AIHA caused by ICI is very rare because it is difficult to detect at an early stage. Once detected, anemia is usually severe. Therefore, immune related adverse reactions should be monitored and identified when ICI is used clinically, especially among chronic users.

Key words: Camrelizumab, Hemolysis, Autoimmunity Hemolytic Anemia, Adverse Drug Reaction, Parotid Gland Carcinoma

CLC Number:

LAN Zhihui, BU Lijia, NING Jie, JIANG Jiemei, YANG Yanbiao. One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 696-698.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250180

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I6/696

References

[1] DELANOY N, MICHOT JM, COMONT T, et al.Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: a Descriptive Observational Study[J]. Lancet Haematology, 2019, 6(1): 48-57.
[2] JOHNSON DB, NEBHAN CA, MOSLEHI JJ, et al.Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity[J]. Nature Reviews Clinical Oncology, 2022, 19: 254-267.
[3] BARCELLINI W, FATTIZZO B.The Changing Landscape of Autoimmune Hemolytic Anemia[J]. Frontiers in Immunology, 2020, 11: 946.
[4] SALIBA AN, XIE Z, HIGGINS AS, et al.Immune-Related Hematologic Adverse Events in the Context of Immune Checkpoint Inhibitor Therapy[J]. American Journal of Hematology, 2021, 96(10): 362-367.
[5] TANIOS GE, DOLEY PB, MUNKER R.Autoimmune Hemolytic Anemia Associated with the Use of Immune Checkpoint Inhibitors for Cancer: 68 Cases from the Food and Drug Administration database and Review[J]. European Journal of Haematology, 2019, 102(2): 157-162.
[6] LEAF RK, FERRERI C, RANGACHARI D, et al.Clinical and Laboratory Features of Auto Immune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors[J]. American Journal of Hematology, 2019, 94(5): 563-574.
[7] KRAMER R, ZAREMBA A, MOREIRA A, et al.Hematological Immune Related Adverse Events after Treatment with Immune Checkpoint Inhibitors[J]. European Journal of Cancer, 2021, 147: 170-181.
[8] UQBA K, FARMAN A, MUHAMMAD SK, et al.Immunotherapy-Associated Autoimmune Hemolytic Anemia[J]. Journal for Immunotherapy of Cancer, 2017, 5: 1-4.
[9] TANJA F, SIMON F, MAYA B, et al.Severe Autoimmune Hemolytic Anemia Following Immunotherapy with Checkpoint Inhibitors in Two Patients with Metastatic Melanoma: a Case Report[J]. Frontiers in Immunology, 2024, 15: 1-9.
[10] MICKAËL M, HOAN-MY N, CLÉMENT B, et al. Immune Checkpoint Inhibitor-Related Cytopenias: about 68 Cases from the French Pharmacovigilance Database[J]. Cancers, 2022, 14(5030): 1-10.
[11] LI CL, SHU JH, LI XG, et al.Excavation and Evaluation of Adverse Reaction Signals of 4 Kinds of Imported PD-1/PD-L1 Inhibitors[J]. China Pharmacy(中国药房), 2022, 33(7): 873-878.
[12] YU X, ZHOU Y, LI Q, et al.Retrospective Analysis of the Literature on Adverse Reactions of 4 Domestic PD-1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2024, 29(8): 887-898.
[13] KOUSEI NK, KAZUYA T, MINORI H, et al.Acute Myeloid Leukemia and Myelodysplastic Syndrome Associated with a Combination of Immune Checkpoint Inhibitor and Platinum-Based Chemotherapy[J]. Thoracic Cancer, 2023, 14: 2225-2228.
[14] BAKACS T, MOSS RW, KLEEF R, et al.Exploiting Autoimmunity Unleashed by Low-Dose Immune Checkpoint Blockade to Treat Advanced Cancer[J]. Scandinavian Journal of Immunology, 2019, 90(6): 1-11.
[15] JÄGER U, BARCELLINI W, BROOME CM, et al. Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommen-dations from the First International Consensus Meeting[J]. Blood Reviews, 2020, 41: 100648.
[16] OGAWA K, ITO J, FUJIMOTO D, et al.Exacerbation of Autoimmune Hemolytic Anemia Induced by the First Dose of Programmed Death-1 Inhibitor Pembrolizumab: a Case Report[J]. Invest New Drugs, 2018, 36(3): 509-512.
[17] YANG ZJ, NING XL, LIU ZM, et al.Severe Anemia Associated with Immune Checkpoint Inhibitor: a Case Report[J]. International Journal of Gynecology(国际妇产科学杂志), 2024, 51(4): 438-441.
[18] Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Chinese Adults[J]. Chin J Hematol(中华血液学杂志), 2023, 44(1): 12-18.
[19] VILLA-CRESPO L, PODLIPNIK S, ANGLADA N, et al.Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival[J]. Cancers (Basel), 2022, 14(5): 1-11.
[20] KROLL MH, ROJAS-HERNANDEZ C, YEE C.Hematologic Complications of Immune Checkpoint Inhibitors[J]. Blood, 2022, 139: 3594-3604.